POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?
Stakeholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of POINT Biopharma Global, Inc. (“POINT”) (NASDAQ: PNT) breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company.
On October 3, 2023, POINT announced that it had entered a deal with Eli Lilly and Company. Under the terms of this agreement, stakeholders will receive $12.50 per share in an all-cash offer.
The investigation concerns whether the POINT board failed to satisfy its duties to the Company stakeholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for POINT shares of common stock especially considering the company has a price target of $27.00 from one analyst.
If you are a stakeholder of POINT and believe the proposed buyout price is too low or you’re interested in learning more about the investigation, please contact lead analyst Jim Baker (firstname.lastname@example.org) at 619-814-4471. If emailing, please include a phone number.
Johnson Fistel, LLP is a stakeholder rights law firm representing individual and institutional investors in stakeholder derivative and securities class action lawsuits. For more information, visit their website http://www.johnsonfistel.com.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471 email@example.com or firstname.lastname@example.org